跳至主要内容
临床试验/DRKS00006861
DRKS00006861已完成不适用

on-interventional studyNational Eklira® Evaluation and Documentation

AstraZeneca GmbH0 个研究点目标入组 1,307 人开始时间: 2014年10月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,307

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
40 Years 至 one(—)
性别
All

入选标准

  • At least 40 years of age;
  • Diagnosed COPD;
  • Current or newly initiated treatment with Eklira® Genuair®;
  • Patient’s informed consent has been obtained.

排除标准

  • Contraindications to the use of anticholinergics in accordance with the Eklira® Genuair® Summary of Product Characteristics (SPC): acute urinary retention, symptomatic prostatic hypertrophy, bladder neck obstruction, or narrow-angle glaucoma;
  • Pregnancy/lactation;
  • Hypersensitivity to aclidinium bromide, atropine or its derivatives, including ipratropium, oxitropium or tiotropium.

研究者

相似试验